10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-C1s Reference Antibody (Riliprubart)

Catalog # APR11234

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P09871
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-mut
Calculated MW	76684

Additional Information


Target/Specificity	C1s
Expression system	CHO

Protein Information


Name	C1S {ECO:0000303|PubMed:3500856, ECO:0000312|HGNC:HGNC:1247}
Function	Component of the complement C1 complex, a multiprotein complex that initiates the classical pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:11445589, PubMed:16169853, PubMed:417728, PubMed:467643, PubMed:6271784, PubMed:6282646, PubMed:6319179, PubMed:70787, PubMed:9422791). C1S is activated following association of the C1 complex with immunoglobulins (IgG or IgM) complexed with antigens to form antigen-antibody complexes on the surface of pathogens (PubMed:34155115). C1S is cleaved and activated by C1R to generate C1s subcomponent heavy and light chains (PubMed:11445589, PubMed:6271784). C1s subcomponent light chain then cleaves and activates C2 and C4, the next components of the classical complement pathway (PubMed:16169853, PubMed:467643, PubMed:6282646, PubMed:6319179, PubMed:6906228, PubMed:70787, PubMed:9422791).
Cellular Location	Secreted. Cell surface. Note=Recruited to the surface of pathogens by the C1Q subcomplex.

Images


Anti-C1s Reference Antibody (Riliprubart) on SDS-PAGE under reducing (R) condition. The purity of the protein is



greater than 95%.



The purity of Anti-C1s Reference Antibody (Riliprubart) is 98.1%, determined by SEC-HPLC.



Immobilized Hu C1s-8His at 2 μg/mL can bind Riliprubart, EC50= 0.007121 μg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.